Eliquis (apixaban), an oral direct factor Xa inhibitor, is indicated for: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults, prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.